{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:12:35Z","timestamp":1782943955520,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.otc.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T02:40:18Z","timestamp":1623206418000},"page":"675-687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biologics in Otolaryngology"],"prefix":"10.1016","volume":"54","author":[{"given":"Nicole C.","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Monfared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.otc.2021.04.001_bib1","series-title":"The road to the biotech revolution: highlights of 100 years of biologics regulation","author":"Bren","year":"2006"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14712598.2015.1009890","article-title":"Biological therapy: chronicling 15 years of progress","volume":"15","author":"Lewiecki","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.otc.2021.04.001_bib3","series-title":"Bennett, Dolin, Blaser, editors. Principles and practice of infectious diseases","first-page":"50","article-title":"Cell-mediated defense against infection","author":"Hohl","year":"2015"},{"issue":"8","key":"10.1016\/j.otc.2021.04.001_bib4","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1182\/blood.V92.8.2668","article-title":"Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 responses","volume":"92","author":"Bonecchi","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/rr41","article-title":"Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease","volume":"2","author":"Greenfeder","year":"2001","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.otc.2021.04.001_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-065X.2011.01026.x","article-title":"Eosinophils: multifaceted biological properties and roles in health and disease","volume":"242","author":"Kita","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.otc.2021.04.001_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/lary.22461","article-title":"When FESS fails: the inflammatory load hypothesis in refractory chronic rhinosinusitis","volume":"122","author":"Bassiouni","year":"2012","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.otc.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.14639\/0392-100X-1417","article-title":"Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach","volume":"37","author":"Gelardi","year":"2017","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/coa.12392","article-title":"Comorbidity has no impact on eosinophil inflammation in the upper airways or on severity of the sinonasal disease in patients with nasal polyps","volume":"40","author":"Uhliarova","year":"2015","journal-title":"Clin Otolaryngol"},{"issue":"3","key":"10.1016\/j.otc.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2500\/ajra.2014.28.4024","article-title":"The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study","volume":"28","author":"Vlaminck","year":"2014","journal-title":"Am J Rhinol Allergy"},{"issue":"23","key":"10.1016\/j.otc.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis","volume":"106","author":"Adelroth","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.otc.2021.04.001_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.otc.2021.04.001_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaip.2014.02.001","article-title":"Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"2","author":"Tsabouri","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2222.2008.03121.x","article-title":"Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma","volume":"39","author":"Kopp","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mai.2002.121949","article-title":"Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis","volume":"109","author":"Kuehr","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.otc.2021.04.001_bib19","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1398-9995.2004.00552.x","article-title":"The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children","volume":"59","author":"Rolinck-Werninghaus","year":"2004","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.otc.2021.04.001_bib20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.otc.2021.04.001_bib22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.otc.2021.04.001_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.otc.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"AB12","DOI":"10.1016\/j.jaci.2017.12.038","article-title":"Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials","volume":"141","author":"Maspero","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10209","key":"10.1016\/j.otc.2021.04.001_bib28","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.otohns.2008.07.0l4","article-title":"History of myringoplasty and tympanoplasty type I","volume":"139","author":"Mudry","year":"2008","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"10.1016\/j.otc.2021.04.001_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MAO.0b013e318245cb51","article-title":"A\u00a0regenerative method of tympanic membrane repair could be the greatest advance in otology since the cochlear implant","volume":"33","author":"Jackler","year":"2012","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1016\/j.otc.2021.04.001_bib31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/MAO.0000000000002628","article-title":"The effectiveness of bFGF in the treatment of tympanic membrane perforations: a systematic review and meta-analysis","volume":"41","author":"Huang","year":"2020","journal-title":"Otol Neurotol"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/019459989210700509","article-title":"Repair of chronic tympanic membrane perforations using epidermal growth factor","volume":"107","author":"Amoils","year":"1992","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"10.1016\/j.otc.2021.04.001_bib33","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/0194599818792019","article-title":"Efficacy of EGF and gelatin sponge for traumatic tympanic membrane perforations: a randomized controlled study","volume":"159","author":"Lou","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"9\u201310","key":"10.1016\/j.otc.2021.04.001_bib34","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/ten.tea.2016.0395","article-title":"Functional outcomes of heparin-binding epidermal growth factor-like growth factor for regeneration of chronic tympanic membrane perforations in mice","volume":"23","author":"Santa Maria","year":"2017","journal-title":"Tissue Eng Part A"},{"issue":"3","key":"10.1016\/j.otc.2021.04.001_bib35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamaoto.2016.3527","article-title":"Declining prevalence of hearing loss in US adults aged 20 to 69 years","volume":"143","author":"Hoffman","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/MAO.0000000000002194","article-title":"Hearing protection, restoration, and regeneration: an overview of emerging therapeutics for inner ear and central hearing disorders","volume":"40","author":"Schilder","year":"2019","journal-title":"Otol Neurotol"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11926-000-0058-y","article-title":"Autoimmune inner ear disease","volume":"2","author":"Roland","year":"2000","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib39","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/coa.12432","article-title":"Current understanding of the pathogenesis of autoimmune inner ear disease: a review","volume":"40","author":"Goodall","year":"2015","journal-title":"Clin Otolaryngol"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/lio2.28","article-title":"AAO: autoimmune and autoinflammatory (disease) in otology: what is new in immune-mediated hearing loss","volume":"1","author":"Vambutas","year":"2016","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"5\u20136","key":"10.1016\/j.otc.2021.04.001_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/00016488609119418","article-title":"Cochlear pathophysiology associated with inner ear immune responses","volume":"102","author":"Woolf","year":"1986","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"10.1016\/j.otc.2021.04.001_bib42","doi-asserted-by":"crossref","first-page":"102310","DOI":"10.1016\/j.amjoto.2019.102310","article-title":"An update on autoimmune inner ear disease: a systematic review of pharmacotherapy","volume":"41","author":"Strum","year":"2020","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"10.1016\/j.otc.2021.04.001_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/annonc\/mdu156","article-title":"Immune biomarkers of anti-EGFR monoclonal antibody therapy","volume":"26","author":"Trivedi","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.otc.2021.04.001_bib44","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/annonc\/mdw428","article-title":"Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer","volume":"27","author":"Ferris","year":"2016","journal-title":"Ann Oncol"},{"issue":"10212","key":"10.1016\/j.otc.2021.04.001_bib45","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"The Lancet"},{"issue":"32","key":"10.1016\/j.otc.2021.04.001_bib46","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.otc.2021.04.001_bib47","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.otc.2021.04.001_bib48","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A\u00a0phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovic","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.otc.2021.04.001_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2013.144","article-title":"Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer","volume":"24","author":"van Schalkwyk","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"18","key":"10.1016\/j.otc.2021.04.001_bib50","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.otc.2021.04.001_bib51","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/hed.25392","article-title":"Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas","volume":"40","author":"Park","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.otc.2021.04.001_bib52","doi-asserted-by":"crossref","first-page":"580141","DOI":"10.3389\/fonc.2020.580141","article-title":"Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease","volume":"10","author":"Di Villeneuve","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.otc.2021.04.001_bib53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","article-title":"Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy","volume":"74","author":"Schmitt","year":"2017","journal-title":"Oral Oncol"},{"issue":"9679","key":"10.1016\/j.otc.2021.04.001_bib54","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"373","author":"Asthagiri","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.otc.2021.04.001_bib55","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.otc.2021.04.001_bib56","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/s41598-020-60156-6","article-title":"Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma","volume":"10","author":"Sagers","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.otc.2021.04.001_bib57","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/0008-5472.CAN-15-1144","article-title":"YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2-EGFR signaling axis","volume":"76","author":"Guerrant","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.otc.2021.04.001_bib58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/neuonc\/noz002","article-title":"Preclinical assessment of MEK1\/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development","volume":"21","author":"Fuse","year":"2019","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.otc.2021.04.001_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","article-title":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes","volume":"144","author":"Lu","year":"2019","journal-title":"J\u00a0Neurooncol"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:53:13Z","timestamp":1758466393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666521000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0030666521000499"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2021.04.001","relation":{},"ISSN":["0030-6665"],"issn-type":[{"value":"0030-6665","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in Otolaryngology","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}